Company intelligence / Profile preview
Ocular Therapeutix
Bedford, Massachusetts, USAocutx.com ↗
- Ownership
- Public · OCUL
- Employees
- ~225
- Development stage
- Phase 3
01
Overview
Ocular Therapeutix has an FDA-approved product DEXTENZA® for post-surgical ocular pain/inflammation and allergic conjunctivitis. Its lead pipeline candidate AXPAXLI™ (OTX-TKI) is in Phase 3 trials for wet AMD with topline data expected Q4 2025. Other candidates are in various stages of clinical development targeting major ophthalmic diseases.
- Therapeutic areas
- OphthalmologyImmunology
- Modalities
- sustained-release drug delivery systems (hydrogel-based)small molecules (e.g., axitinib)corticosteroidsprostaglandin analogs
- Industry
- Biotech
02
Drug pipeline
15 assets14 more assets in the full pipeline.
03
Partnerships
Regeneron Pharmaceuticals – collaboration on extended-release anti–VEGF therapies such as aflibercept formulations
04
Financials
- Market cap
- $1.4B
- Total revenue
- $51.8M
- Enterprise value
- $892.9M
Beyond the preview
Go deeper on Ocular Therapeutix.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ocular Therapeutix.